Jagsonpal Pharmaceuticals has signed a definitive agreement to acquire an 85% equity stake in Mumbai-based Aequitas Healthcare Private Limited, in a move that signals a decisive push into India’s hospital-focused pharmaceutical distribution market.

 

The deal marks a strategic expansion for Jagsonpal into the hospital segment, aligning with its long-term ambition to deepen its footprint in India’s rapidly expanding healthcare ecosystem.

 

Founded in 2017, Aequitas Healthcare operates a distribution-led business supplying pharmaceutical products to leading hospital chains across India. The company reported revenues of Rs. 53 crore in FY26, with an established presence across major institutional accounts.

 

Under the agreement, Jagsonpal will invest Rs. 20.8 crore for the 85% stake, funded entirely through internal accruals. The remaining 15% will continue to be held by Aequitas’ current directors, who will remain associated with the business.

 

Commenting on the acquisition, Manish Gupta, Managing Director, Jagsonpal stated: "The proposed acquisition of Aequitas represents an important strategic milestone for Jagsonpal. It provides us with a ready platform for a meaningful presence in the hospital segment, which now contributes ~10% of pharma industry sales and growing faster. 

 

"We strongly believe that Jagsonpal's portfolio of established brands will greatly benefit from Aequitas' strong institutional relationships, delivering sustainable long-term value to our shareholders."

 

Amrut Medhekar, Chief Operating Officer, Jagsonpal stated: “This transaction is a structurally transformative pivot that moves Jagsonpal from a legacy retail prescription player to Omnichannel Specialty healthcare business in India and is reflective of our long-term commitment to building scalable, high-quality healthcare delivery in India. We look forward to unlocking value through operational excellence, disciplined execution, and patient-centric growth.”